HC Wainwright Analysts Raise Earnings Estimates for XFOR

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for X4 Pharmaceuticals in a note issued to investors on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.02) per share for the quarter, up from their prior forecast of ($0.15). HC Wainwright has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.32) EPS, FY2026 earnings at ($0.23) EPS and FY2027 earnings at ($0.16) EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.07 million.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $3.00 price target on shares of X4 Pharmaceuticals in a research note on Wednesday, March 26th.

X4 Pharmaceuticals Stock Down 6.2 %

Shares of XFOR opened at $0.22 on Monday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. X4 Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $1.60. The stock has a market capitalization of $38.50 million, a price-to-earnings ratio of -2.46 and a beta of 0.39. The stock has a fifty day moving average of $0.42 and a 200-day moving average of $0.51.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. In the last 90 days, insiders sold 202,663 shares of company stock valued at $91,198. 1.62% of the stock is owned by company insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XFOR. Bank of America Corp DE raised its holdings in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares during the period. Point72 Asset Management L.P. raised its stake in shares of X4 Pharmaceuticals by 4.0% during the 4th quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock valued at $477,000 after purchasing an additional 24,948 shares during the period. Wells Fargo & Company MN lifted its holdings in X4 Pharmaceuticals by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after purchasing an additional 26,763 shares in the last quarter. Northern Trust Corp boosted its stake in X4 Pharmaceuticals by 2.9% in the 4th quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock worth $996,000 after purchasing an additional 37,940 shares during the period. Finally, Cantor Fitzgerald L. P. purchased a new position in X4 Pharmaceuticals during the 4th quarter valued at about $30,000. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.